RxDoctor Payments Data

Melissa Albert, MD

Psychiatry · Morgantown, WVNPI 1033313911

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 25.4% of the total.

$4,441in general payments, 2019–2025

Across 291 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$401
  • Alkermes, Inc.$391
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$376
  • Corium, LLC$357
  • Neurocrine Biosciences, Inc.$309
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,436100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,441 in reported general payments places this provider in the 85th percentile of 177 psychiatry providers in West Virginia.

See all psychiatry providers in West Virginia

Medicare billing

Part B allowed, 2024
$38,994
Medicare patients
60
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide40$25,921
RexultiBrexpiprazole16$25,145
VraylarCariprazine Hcl20$24,391
ProzacFluoxetine Hcl12$14,932
FetzimaLevomilnacipran Hcl15$6,768
Paliperidone ErPaliperidone14$5,374
Lurasidone Hcl27$3,847
Methylphenidate ErMethylphenidate Hcl12$2,170
Fluoxetine Hcl76$1,927
Clonazepam137$1,860
Venlafaxine Hcl ErVenlafaxine Hcl81$1,583
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,550
Duloxetine Hcl77$1,451
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine56$1,382
Bupropion XlBupropion Hcl95$1,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$1,128$31,15935 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$183$25,92140 claims
Otsuka America Pharmaceutical, Inc.Rexulti$401$25,14516 claims
Almatica Pharma LLCSertraline Hcl$50$42353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 psychiatry providers in West Virginia.

Other psychiatry in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →